A B STRA CT Fletcher factor-deficient plasma is deficient in prekallikrein and therefore generates no bradykinin upon activation with kaolin. It also possesses a diminished rate of kaolin-activable coagulation and fibrinolysis and possesses a defect in kaolin-activable chemotactic activity. These abnormalities are also corrected by reconstitution with purified prekallikrein. Addition of intact activated Hageman factor corrected the coagulation, fibrinolytic, and chemotactic defects and addition of Hageman factor fragments corrected the fibrinolytic defect and partially corrected the chemotactic defect; neither of these corrected the kiningenerating defect. Although the Hageman factor-dependent pathways appear to be initiated by contact activation of Hageman factor, the kallikrein generated activates more Hageman factor; this feedback is necessary for the Hageman factor-dependent pathways to proceed at a normal rate. It is the absence of this feedback in Fletcher factor-deficient plasma that accounts for the diminished rate of activation of Hageman factor and therefore a diminished rate of activation of the coagulation and fibrinolytic pathways. The ability of prekallikrein to correct the coagulation, fibrinolytic, kinin-generating, and chemotactic defects of Fletcher factor-deficient plasma is consistent with the identity of the Fletcher factor and prekallikrein.
INTRODUCTION
Fletcher factor deficiency, originally described by Hathaway, Belhasen, and Hathaway (1) , is characterized by an abnormality of the intrinsic coagulation pathway in Allen Weiss is a fourth-year medical student at Columbia University Medical School, New York.
Received for publication 15 May 1973 and in revised form 17 September 1973. which the 2-min kaolin-activated partial thromboplastin time is prolonged, but progressively shortens when the duration of incubation with kaolin is increased (2) . The plasma is not deficient in any of the known constituents of the intrinsic coagulation pathway. A factor was subsequently isolated from normal plasma that corrects this coagulation defect and was designated "Fletcher factor" (3) . Recently Wuepper has shown that incubation of Fletcher factor-deficient plasma with kaolin generates no bradykinin because it is deficient in prekallikrein (4) , and Kaplan, Goetzl, and Austen have shown that prekallikrein cannot be isolated from Fletcher factor-deficient plasma (5) . In this communication we report that Fletcher factor-deficient plasma not only possesses abnormalities of coagulation and kinin-generation but also of kaolin-activated fibrinolytic activity and chemotactic activity, each of which is corrected by reconstitution with prekallikrein. The mechanism by which prekallikrein corrects each of these defects is shown to be attributable to the known functions of kallikrein as a kinin-generating enzyme (6) , chemotactic factor (7), and activator of Hageman factor (8) .
METHODS
Bradykinin triacetate (Sandoz Pharmaceuticals Ltd., Basel, Switzerland) was used as the standard for native bradykinin. Hexadimethrine bromide (Aldrich Chemical Co., Inc., Milwaukee, Wisc.); enzo-diffusion fibrin plates (Hyland Division, Travenol Laboratories, Inc., Costa Mesa, Calif.) chromium-51 ('1Cr) (Amersham/Searle Corp., Arlington Heights, Ill.); micropore filters (Millipore Corp., Bedford, Mass.) Gey's medium (Microbiological Associates, Inc., Bethesda, Md.), streptokinase (Hyland Division, Travenol Laboratories, Inc.), and hemostatic phosphatide (cephalin) (Nutritional Biochemical Corporation, Cleveland, Ohio) were obtained as indicated.
Hageman factor-deficient plasma, plasma thromboplastin Serum was processed for the isolation of the Hageman factor prealbumin fragments (9) while fresh plasma (7, 10) was utilized as the source of unactivated or activated Hageman factor, prekallikrein, precursor PTA (pre-PTA), plasminogen proactivator, plasminogen, and a2 macroglobulin. For the preparation of plasma, blood was collected in plastic tubes containing 9 mg of EDTA and 3.6 mg of Polybrene in 0.1 ml of 0.15 M saline for each 10 ml of blood drawn. The tubes were immediately centrifuged at 900g for 20 min at 4VC and the plasma separated with plastic pipettes. Plastic columns and test tubes were utilized throughout all chromatographic procedures to minimize contact activation of Hageman factor. Samples were concentrated by ultrafiltration through a UM-10 membrane (Amicon Corp., Lexington, Mass.). Gel filtration on Sephadex G-100 (9), G-150 (7), G-200 (11) and 6B Sepharose (11) , alkaline disc gel electrophoresis (9) , and isoelectric focusing in polyacrylamide gels (7) were performed as previously described. Protein quantitation on a weight basis was performed-by micro-Kjeldahl analysis.
Unactivated Hageman factor. Unactivated Hageman factor was isolated by a modification of a procedure previously described (10) . 500 ml of human plasma was dialyzed for 8 h against three changes of 0.003 M P04 buffer, pH 8, centrifuged at 2,500 rpm for 15 min to remove any precipitate that had formed, and was applied to a 10 X 100-cm column of quaternary aminoethyl (QAE) Sephadex. The column was washed with 6 liters of equilibrating buffer to collect the effluent containing the proenzymes prekallikrein, pre-PTA, and plasminogen proactivator. Unactivated Hageman factor was then eluted by washing the column with 6 liters of 0.003 M P04 buffer containing 0.06 M NaCl. The unactivated Hageman factor peak was concentrated and the pH brought to 6 .0 by addition of 1 N HCl before chromatography on a 5 X 60-cm column of sulfopropyl (SP) Sephadex equilibrated with 0.003 M P04 buffer, pH 6.0. The column was washed with 1 liter of the equilibrating buffer and then with 1 liter of equilibrating buffer containing 0.09 M NaCl. A linear gradient containing applied. The The hazy broad band observed was shown to represent unactivated Hageman factor by elution and assay of a sliced replicate disc gel.
activated Hageman factor was eluted with a linear gradient of 2 liters 0.003 M P04 buffer, pH 8.0, vs. 0.003 M P04 buffer, pH 8.0, containing 0.2 M NaCl. The unactivated Hageman factor peak was pooled, concentrated to 3 ml, and, when assessed by alkaline disc gel electrophoresis, revealed a single band (Fig. 1) . Elution of a sliced, unstained, disc gel run simultaneously revealed that this band represented unactivated Hageman factor. No identifiable contaminants were seen upon immunoelectrophoresis against anti-whole human serum or after isoelectric focusing in polyacrylamide gels. The final preparation at a concentration of 10 /ug/ml corrected the partial thromboplastin time (PTT) of Hageman factor-deficient plasma from a control time of 30 min to 2.5 min. This represents 0.7 U/ml when the Hageman factor activity of a pool of 10 normal plasmas is arbitrarily set at 1.0 U/ml. It contained approximately 10% activated Hageman factor, since it shortened the PTT of Hageman factor-deficient plasma to Hageman factor fragments. The Hageman factor prealbumin fragments were purified by chromatography of serum on QAE Sephadex, Sephadex G-100, SP Sephadex, and eluation from alkaline disc gels after electrophoresis, as previously described (9) . After dialysis the fragments were concentrated by ultrafiltration and contained no contaminants upon re-electrophoresis on alkaline disc gels. The fragments were routinely utilized at 25 ,ug/ml. When assessed functionally, 5 ,tl of Hageman factor fragment generated 100 ng bradykinin after incubation with 0.2 ml fresh plasma for 2 min at 370C. There was no detectable contamination with any of the Hageman factor substrates, plasminogen, or plasmin.
Hageman factor substrates. Pre-PTA, prekallikrein, and plasminogen proactivator were isolated from the QAE Sephadex effluent obtained from 500 ml of plasma as described above. The proenzyme mixture was concentrated to 100 ml, the 1)H brought to 6.0 with 1 N HCI, and each proenzyme was isolated by sequential chromatography on SP Sephadex, twice on Sephadex G-150 and passage over an anti-IgG immunoadsorbent as previously described (12) . The prekallikrein was utilized in these studies at 10 ,ug/ml and revealed a single band upon alkaline disc gel electrophoresis (Fig. 2) or after isoelectric focusing in polyacrylamide gels. Its isoelectric point was 8.75. 15 Al of this preparation after incubation with 15 Al Hageman factor fragments (25 Ag/ml) generated 150 ng bradykinin from 0.2 ml heat-inactivated plasma. For studies in which the active enzyme kallikrein was used, the prekallikrein prepared through the QAE Sephadex, and SP Sephadex, and the first Sephadex G-150 step was concentrated to 2.5 ml and activated with 0.05 jug Hageman factor fragment by incubation for 24 h at 4°C. The preparation was then found to be fully activated and was fractionated on Sephadex G-150, which separated kallikrein from the Hageman factor fragments. The kallikrein preparation was then passed over the anti-IgG immunoadsorbent. 15 1.l of a 10 ,ug/ml preparation generated 130 ng bradykinin after a 2-min incubation with heat-inactivated plasma (kininogen) (9), a value comparable to the activity generated after activation of prekallikrein at the same protein concentration.
as Macroglobulin. a2 macroglobulin was isolated by the method utilized by Schreiber, Kaplan, and Austen (11) .
Plasminogen. Plasminogen was prepared by affinity chromatography of 100 ml of plasma utilizing a lysine-Sepharose column and epsilon-aminocaproic acid elution as described by Deutsch and Mertz (13) . The plasminogen was then concentrated, dialyzed overnight at 4°C against 0.003 M PO, buffer, pH 8.0, containing 0.15 M NaCl, and further fractionated by Sephadex G-100 gel filtration. The plasminogen peak was pooled, concentrated, and adjusted to 200 Ag/ml for routine use.
Assay procedures
Hagentan factor. Unactivated Hageman factor was assayed by determining its ability to shorten the PTT of Hageman factor-deficient plasma. 50 pl Hageman factor source was incubated for 2 min at 370C with 50 pl "kaolincephalin" reagent (20 mg kaolin plus 20 Al cephalin [6 mg/ml] in 2 ml phosphate-buffered saline) and 50 ,l Hageman factor-deficient plasma in 10 X 75-mm plastic tubes. 50 .l 0.05 M CaC12 was added and the clotting time determined at room temperature. The tubes were tilted each minute and the end point defined as the time interval required for the clot to adhere to the plastic tube.
Activated Hageman factor was assayed in the same manner with the cephalin reagent without any kaolin (14) .
The percentage of activated Hageman factor in the unactivated Hageman factor preparation was determined in the following manner. The activated Hageman factor preparation was diluted so that the PTT in the absence of kaolin was identical to that of the unactivated Hageman factor preparation (2.5 min). The PTT of twofold falling dilutions of the activated Hageman factor preparation was determined and a standard curve obtained by plotting the log PTT vs. percent activated Hageman factor, the undiluted material being 100%. The percent of activated Hageman factor in the precursor preparation was then obtained by determining the PTT of this preparation in the absence of kaolin (8 min) and reading the percentage from the graph (190%).
Hageman factor fragments were assayed by incubation of 0.1 ml sample with 0.2 ml fresh plasma anticoagulated with 624 A. S. Weiss, J. I. Gallin, and A. P. Kaplan EDTA for 2 min at 370C and the bradykinin generated was determined by bioassay.
Kallikreint and prekallikrein. Kallikrein was determined by incubation of 0.2 ml enz)yme source with 0.2 ml heatinactivated plasma prepared as previously described (9) for 2 min at 370C and the bradykinin generated was determined by bioassay. Prekallikrein was assessed by incubation of 0.1 ml prekallikrein source with 0.1 ml Hageman factor fragments (25 Ag/ml) for 5 min at 370C. 0.2 ml heat-inactivated plasma was then added, the mixture incubated for 2 min at 370C and the bradykinin generated determined. Pre-PTA and activated PTA. Pre-PTA and activated PTA were assessed by determining their ability to correct the PTT of PTA-deficient plasma with and without kaolin as previously described (7).
Plasnmin and plasninogen. Plasmin was assayed with
Hyland fibrin plates as previously described (12) . A standard curve relating ring diameter to plasmin concentration was obtained by activating 0.2 ml of a reference preparation of purified plasminogen (12) containing 250 Ag/ml with 140 U of streptokinase for 30 min at 370C; a linear plot relating log concentration plasmin to ring diameter was obtained between 3 and 250 ,g plasmin/ml.
Plasminogen was assayed by incubating 0.2 ml of plasminogen source with 140 U of streptokinase for 30 min at 37°C, and the plasmin generated was determined by the fibrin plate assay.
Plasminogen activator and plasminogen proactivator. Ag/ml) for 1 h at 37°C and the plasmin generated determined by fibrin plate. Plasminogen proactivator was assayed by incubation of 10ll plasminogen proactivator with 10 ,l Hageman factor fragments (25 ,g/ml) for 10 min at 37°C. 20 Al plasminogen (200 jug/ml) was added, the mixture incubated for 1 h at 37°C, and the plasmin generated determined.
Kaolin-activated PTT. The rate of kaolin-activated coagulant activity of Fletcher factor-deficient plasma was assessed by incubating 75 ,l Fletcher factor-deficient plasma with 75 Al cephalin-kaolin reagent (20 mg kaolin plus 20 Al cephalin [6 mg/ml] in 2 ml normal saline) from intervals of 2-10 min at 37°C in 10 X 75-mm plastic tubes.
75 ,l 0.05 M calcium chloride was added and the end point taken as the time required for formation of a fibrin clot. When the effect of purified proteins upon the kaolinactivated PTT was examined, 50 ,l of the sample was added to 50 ul Fletcher factor-deficient plasma. 100 ,l of the cephalin-kaolin reagent was then added and the mixture incubated for either 2 min or 10 min at 37°C. 100 ,l 0.05 M calcium chloride was added and the clotting time determined.
Kaolin-activated fibrinolytic activity. The rate of generation of kaolin-activated fibrinolytic activity of plasma was assessed by a modification of the procedure described by Ogston, Bennett, Ogston, and Ratnoff (15) . To 0.2 ml plasma or 0.1 ml plasma and 0.1 ml test sample were added 0.1 ml kaolin (4 mg/ml in saline) and 3.7 ml 0.01 M sodium acetate buffer, pH 4.8 . After incubation at 37°C, the samples were centrifuged at 2,000 rpm for 10 min at 4°C, the supernate was aspirated, and the precipitate was washed with 2.0 ml 0.01 M sodium acetate buffer and again centrifuged at 2,000 rpm for 10 min at 4°C. The precipitate obtained was dissolved in 0.1 ml 0.01 M P04 buffer, pH 7.5, containing 0.15 AM NaCl, and centrifuged at 2,000 rpm for 5 mim to sediment the kaolin, and the supernate was assayed for plasmin by the fibrin plate assay previously described (12) .
Kaolin-activable chenmotactic activity. Kaolin-activable chemotactic activity was assayed by the method of Gallin, Clark, and Kimball (16) utilizing 'Cr-labeled neutrophils and a double-filter Boyden chamber. Human granulocytes were obtained from normal volunteers. The chemotactic factor was generated by incubation of 0.5 ml serum and either 0.25 ml buffer or test sample with 25 Ml kaolin (20 mg/ml) for 10 min at 37°. The sample was centrifuged at 2,000 rpm for 10 min at 4°C and assayed for chemotactic activity. 0.2 ml of the chemotactic stimulus in 2.0 ml Hanks' solution was placed in the lower compartment and the 5'Cr-labeled cells suspended at a concentration of 2.3 X 100 granulocytes/ml were placed in the upper compartment. The chemotactic chambers were then incubated for 3 h in 100% humidity and 5%o C02 in air. The kinetic studies reported previously showed that the number of granulocytes migrating through the upper filter and incorporated into the lower filter is proportional to the radioactivity in the lower of the two micropore filters (16) . After adjusting for variable specific activity and incorporation of the 'Cr by the granulocytes, chemotaxis was expressed as corrected counts per minute lower filter (cor cpm LF) (16) . The chemotactic response for each experimental condition was the average of three chambers. Student's t test was used to compare the means of different studies.
RESULTS
Abnormalities of coagulation, kinin generation, and fibrinolysis in fletcher factor-deficient plasma. The kaolin-activated PTT of Fletcher factor-deficient plasma was examined by varying the incubation time with kaolin before recalcification. As shown in Fig. 3 , as the incubation time with kaolin was increased from 2 to 10 min, the PTT 15 Al of plasmas deficient in Hageman factor, PTA, PTC, and antihemophilic globulin gave mutual correction of their respective coagulation defects, indicating that the Fletcher factor does not correspond to any of these known coagulation factors.
The kinin-generating capacity of Fletcher factordeficient plasma was next evaluated, as shown in Fig.  4 . Incubation of 0.2 ml Fletcher factor-deficient plasma with 200 Ag kaolin for 2 min at 37°C did not generate any detectable bradykinin (F + kaolin), whereas similar treatment of normal plasma yielded a contraction equivalent to 8 ng/ml bradykinin (N + kaolin). A further increase in incubation time of Fletcher factor-deficient plasma with kaolin did not yield any bradykinin. Incubation of 0.2 ml of Fletcher factor-deficient plasma with 2.5 Ag Hageman factor fragments for 2 min at 37°C also failed to yield bradykinin (F + HFf) suggesting a deficiency of either prekallikrein or kininogen. Addition of 1 ml prekallikrein (10 ijg/ml) to 1 ml of Fletcher factor-deficient plasma followed by activation of 0.4 ml of the mixture with 200 Ag kaolin for 2 min at 37°C resulted in kinin generation equivalent to that of normal plasma. The prekallikrein preparation was free of kallikrein, unactivated Hageman factor, or activated Hageman factor. Thus no bradykinin was generated after incubation of kaolin with prekallikrein in the absence of additional plasma or after, incubation of the prekallikrein with Fletcher factor-deficient plasma in the absence of kaolin. The data therefore indicate that Fletcher factor-deficient plasma is deficient in prekallikrein and possesses both Hageman factor and kininogen.
The possibility that Fletcher factor-deficient plasma might also reveal a fibrinolytic defect was evaluated by determining the rate of plasmin generation by kaolin activation of diluted, acidified plasma. The Fletcher factordeficient plasma was compared with normal plasma and with Hageman factor-deficient plasma. As shown in Fig. 5 , Hageman factor-deficient plasma did not generate any detectable plasmin during a period of incubation with kaolin for 90 min, whereas normal plasma rapidly generated plasmin activity. Fletcher factordeficient plasma gave an intermediate result in which the generation of fibrinolytic activity was slow but gradually reached normal levels. Further incubation of either normal plasma or Fletcher factor-deficient plasma for periods extending to 4 h revealed progressive diminution of detectable plasmin presumably secondary to the action of plasmin inhibitors.
Correction of the coagulation and fibrinolytic defects in Fletcher factor-deficient plasma by reconstitution with prekallikrein. Since the kinin-generating defect of Fletcher factor-deficient plasma appeared to be caused by a deficiency of the Hageman factor substrate prekallikrein, the relationship of prekallikrein and the other Hageman factor substrates, pre-PTA, and plasminogen proactivator to the observed coagulation and fibrinolytic defects was next examined. The QAE Sephadex effluent obtained from 500 ml plasma containing prekallikrein, pre-PTA, and plasminogen proactivator was fractionated on SP Sephadex and assayed for each proenzyme as shown in Fig. 6A . The various fractions were then assayed for their ability to correct the coagulation and fibrinolytic defects of Fletcher factor-deficient plasma. As shown in Fig. 6B , both defects were corrected by those fractions containing prekallikrein and plasminogen proactivator but not by those containing pre-PTA. The mixture of prekallikrein and plasminogen proacti- vator was then fractionated on Sephadex G-150, which resulted in further resolution of prekallikrein and plasminogen proactivator (Fig. 7A ). When these fractions were assessed for their ability to correct the coagulation and fibrinolytic defects of Fletcher factor-deficient plasma, both defects were corrected by the prekallikreincontaining fractions (Fig. 7B) . Five different normal plasmas were processed in the above fashion; in each instance the prekallikrein-containing fractions corrected both the coagulation and fibrinolytic defects of Fletcher factor-deficient plasma.
A chemotactic defect in Fletcher factor-deficient serum.
When prekallikrein and plasminogen proactivator are activated by Hageman factor, both the kallikrein and plasminogen activator generated are chemotactic for human neutrophils (5) . To evaluate a possible chemotactic defect in Fletcher factor-deficient serum, normal serum and Fletcher factor-deficient serum were assayed for chemotactic activity before and after incubation with kaolin. As shown in Fig. 8 , a prominent increase in chemotactic activity was observed in the normal serum after a 1 5-min incubation with kaolin (P < 0.001).
However, no increase in chemotactic activity was observed when Fletcher factor-deficient serum was assayed under the same conditions (P > 0.05). Reconstitution of Fletcher factor-deficient serum to yield a final concentration of 3 Ag prekallikrein/ml did not yield an increase in chemotactic activity in the absence of kaolin (P > 0.05). Kaolin activation of Fletcher factor-deficient serum -reconstituted to 3 ,sg prekallikrein/ml yielded chemotactic activity comparable to that observed after kaolin treatment of normal serum (P > 0.05) and significantly greater than kaolin-activated Fletcher factordeficient serum without prekallikrein (P < 0.001). A mixture of prekallikrein and kaolin alone had no chemotactic activity (mean 183±26 cor cpm LF). The magnitude of the chemotactic activity generated by kaolin was comparable to that observed with immune complex or endotoxin activation of normal serum (17) . The kaolin was free of endotoxin as assessed by the limulus assay (18) . The chemotactic activity could be generated in the presence of 5 mM EDTA, which prevents the generation of complement-dependent chemotactic factors (19) C5, which was previously shown to inactivate C5a, the major complement-derived chemotactic factor resulting from in vitro activation of serum (17) . Correction of the coagulation, fibrinolytic, and chemotactic defects by reconstitution with intact activated Hageman factor or Hageman factor fragments. The mechanism by which the Fletcher factor was thought to correct the coagulation defect in Fletcher factor-deficient plasma was by interacting with Hageman factor or PTA or both (3) . However, the observation that Fletcher factor-deficient plasma also possesses a fibrinolytic defect that is corrected by addition of prekallikrein suggests that it might act upon Hageman factor, the one factor common to both the intrinsic coagulation and fibrinolytic pathways. Reconstitution of Fletcher factor-deficient plasma with either intact activated Hageman factor or Hageman factor fragments was therefore attempted in order to determine whether prekallikrein might act at the Hageman factor step. Fletcher factordeficient plasma was reconstituted so that it contained 5
,ug/ml of either purified prekallikrein, intact activated Hageman factor, or Hageman factor fragments and assayed for kaolin-activated coagulation and fibrinolytic activities. Each assay was performed in quadruplicate.
The results are reported as the mean of four determinations and the standard errors are indicated in each figure.
As shown in Fig. 9 , after a 10-min incubation with kaolin, the PTT was 2 min and was not further increased when reconstituted with activated Hageman factor or Hageman factor fragments. However, a 2-min incubation with kaolin revealed a prolonged PTT of 8 min, its control (P < 0.001). A comparison of the 2-min PTT of the Fletcher factor-deficient plasma control (7.9 min) with the 2-min PTT obtained after addition of Hageman factor fragments (7.2 min) yields a small, yet significant difference, P < 0.05 but > 0.02. Reconstitution with 5 /g/ml unactivated Hageman factor did not accelerate the PTT after a 2-min incubation with kaolin. The assay for kaolin-activated fibrinolytic activity utilized an incubation time of 10 min, at which time Fletcher factor-deficient plasma generates little plasmin activity (Fig. 5) . As shown in Fig. 10 , the normal plasma control generated 18 ug plasmin/ml after a 10-min incubation; however, Fletcher factor-deficient plasma generated only 4 sAg plasmin/ml. The fibrinolytic defect was corrected by reconstitution of Fletcher factor-deficient plasma with either prekallikrein, intact activated Hageman factor, or Hageman factor prealbumin fragments (P < 0.001). Similarly, the chemotactic defect of Fletcher factor-deficient serum was evaluated after a 10-min incubation with kaolin before and after reconstitution to contain 5 /Lg/ml prekallikrein, intact activated Hageman factor, or Hageman factor prealbumin fragments (Fig. 11) . Incubation of normal serum with kaolin significantly increased the chemotactic activity (P < 0.001), but kaolin treatment of Fletcher factordeficient serum did not (P > 0.05). Reconstitution of Fletcher factor-deficient serum with prekallikrein or intact activated Hageman factor completely corrected the chemotactic defect (P < 0.001) whereas addition of Hageman factor fragments gave only partial correction compared to addition of either prekallikrein (P < 0.05) or intact activated Hageman factor (P < 0.01 ). FIGURE 9 Comparison of the mean+SE (four experiments) of the 10-min and 2-min PTT of Fletcher factor-deficient plasma before and after reconstitution with 5 ,ug/ml of either intact activated Hageman factor or Hageman factor fragments. The control PTT of the Fletcher factor-deficient plasma (Fc) is indicated for either a 10-min or 2-min incubation with kaolin followed by the PTT of Fletcher factor-deficient plasma reconstituted with either intact acti- Activation of unactivated Hagernan factor with kallikrein. The ability of intact activated Hageman factor to reconstitute the coagulation, fibrinolytic, and chemotactic defects of Fletcher factor-deficient plasma suggests that prekallikrein affects these functions by accelerating the conversion of unactivated Hageman factor to activated Hageman factor (20) . However, activated Hageman factor or its fragments convert prekallikrein to kallikrein (9, 14, 21, 22 (8) . Since prekallikrein corrected both the coagulation and fibrinolytic defects of Fletcher factor-deficient plasma, it appeared likely that prekallikrein was acting at Hageman factor, the only protein known to be common to both pathways. Correction of the coagulation and fibrinolytic defects of Fletcher factordeficient plasma by addition of intact activated Hageman factor indicated that the requirement for prekallikrein in both these pathways had been bypassed and that prekallikrein does indeed contribute to Hageman factor activation in whole plasma. The ability of the Hageman factor prealbumin fragments to correct the fibrinolytic defect but not the coagulation defect is consistent with the observation that the fragments are fully active in the fibrinolytic pathway (12) but possess only 2-5% of the clotting activity of the parent molecule (10) . The pathways initiated by activated Hageman factor are shown diagrammatically in Fig. 12 , indicating the positions of known enzymatic feedback and the functions derived from each pathway. Although plasmin is capable of converting unactivated Hageman factor to activated Hageman factor in the fluid phase, addition of 50 /g/ml of plasmin to Fletcher factor-deficient plasma gave minimal correction to its kaolin-activated PTT, whereas addition of 50 Ag/ml plasmin plus 2 ltg/ ml kallikrein was fully corrective. However, less efficient fluid phase activation of Hageman factor by plasmin or other enzymes that possess a feedback capability may account for the gradual normalization of the coagulation and fibrinolytic defects of prekallikreindeficient plasma when the incubation time is increased. Although the activation of Hageman factor in plasma is initiated by contact, the ability of kallikrein to convert unactivated Hageman factor to activated Hageman factor in the fluid phase is required for the Hageman factor-dependent pathways to proceed at a normal rate. The ability of prekallikrein to correct the coagulation, fibrinolytic, kinin-generating, and chemotactic defects of Fletcher factor-deficient plasma is consistent with the conclusion that the Fletcher factor is prekallikrein.
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